Nicholas Choong

Company: Seagen

Job title: VP, Clinical Development

Seminars:

Delving into Disitamab Vedotin: A Novel HER2 ADC 12:15 pm

Disitamab vedotin is a HER2 ADC with an antibody designed to maximise drug delivery with higher affinity and internalisation rate as compared to trastuzumab in preclinical models Highlighting DV’s encouraging monotherapy clinical data across a range of HER2 expressing solid tumours, and combination activity with anti-PD1 in urothelial cancerRead more

day: Track C - Day 1 - AM